Amgen (AMGN) tops profit expectations, revenue rises 5%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amgen sales rise, but shares off as investors await obesity data
October 31, 2023 7:10 AM EDTBy Deena Beasley
(Reuters) -Amgen on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition this month of Horizon Therapeutics and its shares fell nearly 4%.
Sales of some high profile medicines also fell short of expectations, likely contributing to the share move.
Amgen said it expects to announce findings from an early-stage trial of experimental obesity pill AMG786 in the first half of next year, and to have results from a mid-stage trial of a different, injected obesity candidate, AMG133, by late next year.
"Overall... More
Amgen (AMGN) Tops Q3 EPS by 28c; Raises Outlook
October 31, 2023 7:03 AM EDTAmgen (NASDAQ: AMGN) reported Q3 EPS of $4.96, $0.28 better than the analyst estimate of $4.68. Revenue for the quarter came in at $6.9 billion versus the consensus estimate of $6.92 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $18.20-$18.80, versus the consensus of $17.31. Amgen sees... More
Amgen (AMGN) PT Raised to $272 at UBS
October 30, 2023 9:21 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $272.00 (from $260.00) while maintaining a Neutral rating.... More
